Iconic Therapeutics is a subsidiary of Endpoint Health, specializing in the development of innovative therapies for acute and chronic inflammatory conditions, ophthalmic diseases, and oncology. Their research focuses on targeting tissue factor, a key factor in modulating cytokines and driving oncogenic processes, to provide effective treatments for conditions such as acute lung injury, vasculitis, age-related macular degeneration, and solid tumors.
With a strong scientific advisory board and strategic partnerships, including one with Exelixis for their oncology program, Iconic Therapeutics is at the forefront of advancing novel therapies that have the potential to significantly impact patient outcomes in various disease areas.
Generated from the website